Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
For patients with resectable early-stage gastric and gastroesophageal junction cancers
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
Subscribe To Our Newsletter & Stay Updated
